Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis

Authors

  • Christopher T. Bever Jr Dr., MD,

    Corresponding author
    1. Department of Neurology, School of Medicine, School of Pharmacy, University of Maryland
    2. Research Service, Department of Veterans Affairs Medical Centre, Baltimore, MD
    3. Neurology Services, Department of Veterans Affairs Medical Centre, Baltimore, MD
    • Department of Neurology, University of Maryland Hospital, N4W46, 22 South Greene St., Baltimore, MD 21201
    Search for more papers by this author
  • James Leslie PhD,

    1. Clinical Pharmocokinetics Laboratory, School of Pharmacy, University of Maryland
    Search for more papers by this author
  • David L. Camenga MD,

    1. Department of Neurology, School of Medicine, School of Pharmacy, University of Maryland
    Search for more papers by this author
  • Hillel S. Panitch MD,

    1. Department of Neurology, School of Medicine, School of Pharmacy, University of Maryland
    2. Neurology Services, Department of Veterans Affairs Medical Centre, Baltimore, MD
    Search for more papers by this author
  • Kenneth P. Johnson MD

    1. Department of Neurology, School of Medicine, School of Pharmacy, University of Maryland
    Search for more papers by this author

Abstract

Ten patients with multiple sclerosis (MS) were enrolled in a preliminary trial of the potassium channel blocker, 3,4-diaminopyridine, to evaluate drug toxicity and pharmacokinetics. The patients were treated with oral 3,4-diaminopyridine, first with increasing single doses up to 100 mg and then with divided dosage for up to 3 weeks. Paresthesias were reported by all patients and abdominal pain was dose limiting in 6 patients. 3,4-Diaminopyridine levels and half-life varied widely from patient to patient. Cerebrospinal fluid levels of 3,4-diaminopyridine were about 10% of those in serum. Neither seizures nor epileptiform changes on electroencephalographic examination occurred. Small reversible improvements in specific neurological deficits were seen on examination in all patients and reversible improvement in visual evoked response latencies were found in 2 patients. These results suggest that further study of 3,4-diaminopyridine in patients with MS is warranted.

Ancillary